Seer 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- 3rd quarter 2026 revenue was $4.0 million, compared with $3.1 million in the 2nd quarter, driven by higher product revenue from increased instrument shipments and new customer agreements.
- Product revenue was $2.8 million, service revenue was $1.1 million, related party revenue was $0.1 million, and other revenue was approximately $67,000.
- Gross profit was approximately $1.9 million, representing a gross margin of 47%, down 130 basis points sequentially.
- Total operating expenses were $16.5 million, including $1.2 million of stock-based compensation, compared with $21.5 million, including $3.6 million of stock-based compensation, in the 3rd quarter of 2025.
- Net loss was $13.7 million, compared with $18.2 million in the 3rd quarter of 2025.
- For the 9 months ended September 30th, 2026, net cash used in operating activities was approximately $34.5 million and free cash flow was approximately negative $34.8 million.
- Seer ended the quarter with approximately $198 million in cash, cash equivalents, and investments.
- During the 3rd quarter, Seer repurchased approximately 61,000 Class A common shares at an average price of $1.64 per share; through September 30th, it had repurchased approximately 13.5 million shares at a volume-weighted average price of $1.85 cents per share.
- PRECISE-SG100K investigators quantified approximately 8,800 protein groups across 9,658 plasma samples and approximately 88,000 peptides per sample, with consistent performance across 126 processing batches and no reported sample failure.
- The PRECISE investigators identified more than 4,200 proteins with significant CysPQTL associations, reported 2,762 genetic protein associations not reported across the 12 reference studies used for comparison, and connected proteins to 71 health-related traits.
- A Clinical Proteomics study found that ProteoGraph XT with the Orbitrap Exploris 480 identified an average of approximately 6,060 proteins per sample and had a missing protein measurement rate of 1.9%.
- Seer said publications, preprints, and reviews describing research using ProteoGraph totaled 116, up from 95 at the last quarterly report; in Q&A, management said the publication count was 160 and expected to enter 2027 with a run rate of 100 publications a year.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this event is being recorded. I would now like to turn the conference over to Marissa Bych of Gilmartin Group. Please go ahead. Thank you.
Earlier today, Seer released financial results for the quarter ended September 30, 2026. If you have not received this news release, or if you would like to be added to the company's distribution list, please send an email to investor@seer.bio. In addition, during today's conference call, we will be referencing a slide presentation that can be accessed on the Events and Presentations section of Seer's Investor Relations website. Participating today from Seer is Omid Farokhzad, Chief Executive Officer and Chair of the Board, and Charles Endweiss, Treasurer, Principal Financial Officer, and Principal Accounting Officer. Before we begin, I would like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.
Additional information regarding these risks and uncertainties appears in the section titled Forward-Looking Statements in the press release Seer issued today. For a more complete list and description, please see the Risk Factors section of the company's quarterly report on Form 10-Q for the quarter ended September 30, 2026, and in its other filings with the Securities and Exchange Commission. Except as required by law, Seer disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today. With that, I would like to turn the call over to Omid.
Thank you, Marissa, and thank you all for joining us this afternoon. This quarter, our customers continue to demonstrate what Proteograph makes possible, from new biological discoveries in population-scale studies to emerging applications in AI. Established customers continue to purchase consumables, and new large biopharma customers adopted the Proteograph Product Suite for use in their own laboratories. These developments reinforce my conviction in the value of our technology and the business opportunity ahead for Seer. Our opportunity is to make deep and vast proteomics a routine part of research programs that require a more complete understanding of biology. Proteograph substantially expands what researchers can learn from mass spectrometry while allowing them to use existing LC-MS infrastructure. As this value becomes clearer across more applications, we have the opportunity to expand both our customer base and the use of the platform within each account.
The business model connects directly to that use. Each additional sample processed with the Proteograph requires assay consumables. A successful study can lead to a larger cohort, follow-up research, or adoption by another team within the same institution. Our Technology Access Center, or TAC, and service providers give customers additional ways to access the technology. This allows us to serve researchers at different stages of adoption and build repeat revenue as the programs develop. We see that model at work in established accounts, including customers that have purchased consumables across multiple consecutive quarters. Our commercial priority is to build on these relationships, help customers expand their research programs, and bring the same value to additional accounts. Revenue for the third quarter was $4 million, compared with $3.1 million in second quarter.
Customer funding constraints and longer purchasing timelines continue to affect the pace of revenue conversion, and we are updating our full-year outlook to $13.5 million-$14.5 million. Charles will discuss the results and outlook in detail. We remain focused on converting funded opportunities and expanding repeat customer use. The activist campaign and subsequent acquisition proposals also led some customers to ask about the direction of Seer's future and the long-term support of their research programs. We have spent time directly addressing those questions. As announced on October 29th, the special committee has completed its review, and Seer will remain an independent public company. This gives us a clear message for customers about our continued commitment to innovation, service, and support. I am encouraged by the recovery we are seeing in our pipeline.
Publications, preprints, and reviews describing research conducted using the Proteograph now totals 116, up from 95 at our last quarterly update. I want to highlight the discoveries researchers are advancing, what this growth evidence means for the use of the Proteograph, and how it supports commercial opportunity we are pursuing. Turning to slide three. Let me turn to the scientific evidence from the PRECISE-SG100K cohort presented at the 2026 Human Proteome Organization World Congress, or HUPO. PRECISE-SG100K is Singapore's population health study of approximately 100,000 residents of Chinese, Malay, and Indian ancestry, designed to understand how genetics, biology, lifestyle, and environment influence health and disease. Within this program, investigators selected our Proteograph workflow combined with Thermo Fisher's Orbitrap Astral Mass Spectrometry to deeply characterize the plasma proteome of 10,000 participants, complementing affinity-based measurements within the broader study.
Professor John Chambers, Chief Scientific Officer of PRECISE and lead investigator of PRECISE-SG100K, presented preliminary findings. Across 9,658 plasma samples, the Proteograph Astral workflow quantified approximately 8,800 protein groups across this study and approximately 88,000 peptides per sample. Performance was consistent across 126 processing batches with no reported sample failure. Population studies require both depth and reliable execution across thousands of samples, and these results demonstrate the ability of our workflow to deliver both. As subsequently reported by Thermo Fisher Scientific, the PRECISE investigators identified more than 4,200 proteins with significant cis-pQTL associations, which link nearby genetic variations with measured protein abundance. They also reported 2,762 genetic protein associations that had not been reported across the 12 reference studies used for comparison and connected proteins to 71 health-related traits.
When combined with disease genetics and other evidence, these relationships can help researchers investigate disease mechanism and prioritize potential therapeutic targets. The PRECISE-SG100K illustrates a central aspect of Seer's value proposition. Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Published studies and customer presentations using matched plasma samples have repeatedly demonstrated that conventional mass spectrometry workflows without the Proteograph achieve approximately 10%-15% of the protein coverage achieved when Proteograph is paired with a mass spectrometry. Used alongside advanced mass spectrometers, Proteograph substantially expands the biological information available for discovery. Just as 10x Genomics enabled researchers to use DNA sequencing to resolve biology at the level of individual cells, Seer enables researchers to use mass spectrometry to explore a much deeper landscape of circulating proteins.
By bringing thousands of additional proteins within reach of measurement, Proteograph opens new opportunities to uncover genetic protein relationships, investigate disease mechanism, and identify potential therapeutic targets. This is the discovery capability Seer brings to population-scale research. The PRECISE team is now beginning to analyze the peptide-level data, creating opportunities to investigate protein variants and isoforms beyond the protein-level findings reported to date. For Seer, studies of this scale demonstrate both scientific value and the ability to support substantial sample processing programs. Turning to slide four. An independent study published in Clinical Proteomics provides another example of our differentiation. Researchers at CHA University in South Korea compared seven plasma preparation approaches using accessible mass spectrometry instrumentation. Proteograph XT, together with the Orbitrap Exploris 480, delivered the greatest proteome coverage, identifying an average of approximately 6,060 proteins per sample and the lowest rate of missing protein measurements at 1.9%.
These findings demonstrate that Proteograph enables deep proteomic coverage even in laboratories using earlier generation of mass spectrometers. Alongside this performance evidence, we have made important progress in protecting the technology behind it. Our intellectual property portfolio now includes more than 250 patent and patent applications, including 88 issued patents. On November 5th, we announced a significant development in our ITC action with Brigham and Women's Hospital against Nanomics. Nanomics stopped defending the investigation, and the ITC's investigative staff subsequently recommended granting the full exclusion and cease and desist order we requested. The commission's final determinations remains pending and is expected by the year-end. This is meaningful progress in defending our foundational intellectual property. Our customers commit precious samples, time, and resources to scientific discovery, and we will vigorously protect the innovation they rely on.
The downstream impact of the Proteograph-enabled discoveries also illustrated by PrognomiQ's ProVue Lung, the blood-based lung cancer detection test developed from biomarkers discovered using our technology. PrognomiQ commercially launched ProVue Lung in November 2025 as a laboratory-developed test, or an LDT, and has reported early results from its ongoing real-world clinical evaluation. In recent conference presentation, PrognomiQ's Chief Technology Officer, Bruce Wilcox, described how the protein biomarkers from the original discovery study were independently replicated using both targeted mass spectrometry and immunoassays in a separate patient cohort. The findings supported translation into a multiplex immunoassay for the launch of ProVue Lung. He also reported that the program progressed from initial Proteograph-based discovery to a validated laboratory-developed test in 31 months, with clinical deployment through Allegheny Health Network and Penn Highlands Healthcare.
This is a concrete example of how broader biological information at the discovery stage can support the development of a clinical assay. Turning to slide five. AI is shaping biology, and the capabilities of a model depend on the data it learns from. Proteograph-enabled mass spectrometry produces information at the spectral, peptide, and protein levels. Researchers can use this data to investigate protein abundance, peptide-level differences, and signals that conventional identification-based analysis have yet to fully characterize. Professors Sangwon Lee and Jaewoo Kang of Korea University presented preliminary findings for more than 5,500 plasma samples at the ASMS and HUPO conference this year. Their work combines deep Proteograph-enabled plasma measurements with an ID-Free AI proteomics approach that uses features from both identified and unidentified spectral signals. Preliminary results showed improved overall cancer classification performance compared with models using only identified peptide features.
We believe AI can become an important driver of demand for deep unbiased proteomics. When researchers are searching for new biological relationships, the information available to a model shapes what it can discover. Proteograph allows them to explore thousands of proteins beyond pre-defined panels while retaining peptide-level information and identifying spectral signals that can be revisited as analytical methods advance. The Korea University work provides an early example of that opportunity. As more organizations use AI to investigate biology, we see an opportunity to help them generate the deep proteomic datasets those efforts require. That scientific interest is now translating into commercial activity. Our priority is to translate that scientific value into sustained commercial growth. Under Tony Bazarko's leadership as our Chief Commercial Officer, we're concentrating customer engagement and resources on accounts with the potential to generate meaningful repeat revenue.
Tony and I are also making AI-driven research an explicit commercial priority, focusing on organizations that need deep proteomic data and have funded programs that can translate into sample volume. Within existing accounts, we're working to expand successful studies into additional funded programs and introduce Proteograph to other research teams. In new accounts, we're focusing on opportunities with a clear scientific use case, funding, and a defined path to sample processing. We're also in active discussion with public and private population-scale cohorts about how Proteograph can support their next studies. We're also focused on biopharma, where we have signed several new large pharmaceutical customers this year that purchase instrument and consumables for their studies. Pharmaceutical companies can use proteomics across multi-year research programs to investigate mechanism of action, resistance biology, and biomarkers. Our objective is to help initial adoption develop into larger studies and broader use across research teams.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
